Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
MGRM 
Monogram Orthopaedics Inc. Common Stock (MGRM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: MGRM (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $8.4
1 Year Target Price $8.4
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -16.4% | Avg. Invested days 27 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 234.86M USD | Price to earnings Ratio - | 1Y Target Price 8.4 |
Price to earnings Ratio - | 1Y Target Price 8.4 | ||
Volume (30-day avg) 1 | Beta 0.7 | 52 Weeks Range 1.92 - 6.02 | Updated Date 08/29/2025 |
52 Weeks Range 1.92 - 6.02 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.54 |
Earnings Date
Report Date 2025-08-22 | When - | Estimate -0.11 | Actual -0.16 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -72.9% | Return on Equity (TTM) -228.82% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 196468349 | Price to Sales(TTM) 243.53 |
Enterprise Value 196468349 | Price to Sales(TTM) 243.53 | ||
Enterprise Value to Revenue 230.43 | Enterprise Value to EBITDA -5.1 | Shares Outstanding 36159600 | Shares Floating 31030126 |
Shares Outstanding 36159600 | Shares Floating 31030126 | ||
Percent Insiders 53.45 | Percent Institutions 4.96 |
Upturn AI SWOT
Monogram Orthopaedics Inc. Common Stock
Company Overview
History and Background
Monogram Orthopaedics Inc. was founded to develop and commercialize personalized orthopedic implants using advanced imaging and robotics. They focus on improving patient outcomes and surgical efficiency through customized solutions.
Core Business Areas
- Personalized Implants: Design and manufacturing of patient-specific orthopedic implants based on CT imaging.
- Robotics and Surgical Guidance: Development of robotic surgical systems and software for precise implant placement.
Leadership and Structure
Benjamin Sexson is the CEO. The company operates with a functional structure, focusing on engineering, manufacturing, and commercialization.
Top Products and Market Share
Key Offerings
- Personalized Knee Implants: Patient-specific total knee arthroplasty (TKA) implants designed for optimal fit and function. Market share is still emerging as the product gains traction. Competitors include Zimmer Biomet (ZBH), Stryker (SYK), and DePuy Synthes (JNJ).
- mBESS Robotic System: A surgical robot designed to assist in the precise placement of personalized knee implants. Early in commercialization. Competitors include Stryker's Mako system (SYK) and Zimmer Biomet's ROSA (ZBH).
Market Dynamics
Industry Overview
The orthopedic implant market is large and growing, driven by an aging population and increasing demand for joint replacement surgeries. There is a growing trend toward personalized medicine and robotic-assisted surgery.
Positioning
Monogram Orthopaedics is positioned as an innovator in the personalized implant and robotic surgery space, differentiating itself through its focus on patient-specific solutions.
Total Addressable Market (TAM)
The total addressable market for orthopedic implants is estimated at $50 billion globally. Monogram's personalized approach allows it to target a premium segment of this market, focusing on patients who may not be well-served by traditional implants.
Upturn SWOT Analysis
Strengths
- Personalized Implant Technology
- Robotic Surgical System
- Potential for Improved Patient Outcomes
- Intellectual Property Portfolio
Weaknesses
- Limited Commercialization History
- High Manufacturing Costs
- Reliance on Regulatory Approvals
- Need for Surgeon Training
Opportunities
- Growing Demand for Personalized Medicine
- Expansion into Other Orthopedic Applications
- Partnerships with Hospitals and Surgeons
- International Market Expansion
Threats
- Competition from Established Orthopedic Companies
- Reimbursement Challenges
- Technological Advancements by Competitors
- Product Liability Risks
Competitors and Market Share
Key Competitors
- ZBH
- SYK
- JNJ
- SMED
Competitive Landscape
Monogram Orthopaedics competes with established players. Monogram has an advantage in personalization but faces challenges in scale and market access.
Growth Trajectory and Initiatives
Historical Growth: Assess historical revenue growth based on limited commercial sales.
Future Projections: Evaluate analyst estimates for future revenue growth, market penetration, and profitability.
Recent Initiatives: Track recent product launches, partnerships, and regulatory approvals.
Summary
Monogram Orthopaedics is an innovative company focused on personalized orthopedic implants and robotic surgery. Its personalized approach offers potential benefits, but its commercialization is early stage and competes with much larger companies. Success depends on proving improved outcomes, securing regulatory approvals, and scaling manufacturing effectively, all while maintaining sufficient funding.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on available data and is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Monogram Orthopaedics Inc. Common Stock
Exchange NASDAQ | Headquaters Austin, TX, United States | ||
IPO Launch date 2023-05-18 | Chairman of the Board, President & CEO Mr. Benjamin Sexson C.F.A. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 27 | |
Full time employees 27 | |||
Monogram Technologies Inc. engages in developing surgical robot to enable placement of patient optimized orthopedic implants in the United States. It intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures. The company was formerly known as Monogram Orthopaedics, Inc. and changed its name to Monogram Technologies Inc. in May 2024. Monogram Technologies Inc. was founded in 2015 and is headquartered in Austin, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.